Efficacy of Combined PEV3A Virosomal Vaccine and FP9-MVA ME-TRAP Prime Boost Regimen
Assessment of Protection Against Malaria by Sporozoite Challenge of Healthy Adults Vaccinated With the Virosomal Vaccine PEV3A and FP9-MVA ME-TRAP. A Phase I / IIa Controlled Challenge Trial
Sponsor: Medical Research Council
Listed as NCT00408668, this PHASE1/PHASE2 trial focuses on Malaria and Malaria, Falciparum and remains completed. Sponsored by Medical Research Council, it has been updated 4 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
4 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
First recorded
Aug 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Medical Research Council
- Pevion Biotech Ltd
- Swiss Tropical & Public Health Institute
- University of Oxford
- Walter Reed Army Institute of Research (WRAIR)
For direct contact, visit the study record on ClinicalTrials.gov .